Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) unveiled promising results from its Open-Label Extension (OLE) study evaluating ZYN002, a potential treatment for Fragile X syndrome (FXS). The ...

After breaking out of a descending channel, FXS has reclaimed the $3.96-$5.02 resistance zone. Overextended signals suggest a potential short-term pullback or consolidation. Support at $3.96 and ...

Standard equipment includes the features that come with this vehicle. Select Your Options Choose options to include in this vehicle value. MOTORCYCLES/ATVS/UTILITY ...

Standard equipment includes the features that come with this vehicle. Select Your Options Choose options to include in this vehicle value. MOTORCYCLES/ATVS/UTILITY ...

The data showed clinically meaningful improvements in irritability-related symptoms prevalent in individuals with FXS. There are currently no U.S. Food & Drug Administration (FDA) approved ...

The IGN World Guide for FX's Alien: Earth launched today, Earth Day 2025, and it provides fans of the acclaimed sci-fi horror ...